メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
西山 直隆
准教授, 博士（医学） 札幌医科大学 2011年8月
腎泌尿器科学講座
h-index
558
被引用数
14
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2004
2025
年別の研究成果
概要
フィンガープリント
ネットワーク
プロジェクト
(1)
研究成果
(36)
コース
(6)
類似のプロファイル
(6)
フィンガープリント
Naotaka Nishiyamaが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Antiinfective Agent
15%
Bladder
20%
Bladder Cancer
46%
Bone Metastasis
23%
Cancer Chemotherapy
14%
Cancer Specific Survival
29%
Castration Resistant Prostate Cancer
26%
Chemotherapy
50%
Cisplatin
21%
Clear Cell Renal Cell Carcinoma
30%
Cystectomy
79%
Disease
13%
Docetaxel
11%
Febrile Neutropenia
12%
Hazard Ratio
18%
Immune Checkpoint Inhibitor
12%
Intravesical Drug Administration
14%
Kidney Metastasis
25%
Laparoscopic Surgery
17%
Lymph Node
24%
Lymphocyte
15%
Malignant Neoplasm
29%
Multivariate Analysis
11%
Muscle Invasive Bladder Cancer
29%
Mycobacterium Bovis BCG
15%
Neoadjuvant Chemotherapy
26%
Neoplasm
26%
Nephroureterectomy
23%
Neutrophil
15%
Nivolumab
32%
Non Muscle Invasive Bladder Cancer
100%
Overall Survival
49%
Pembrolizumab
26%
Prednisolone
12%
Prognostic Factor
22%
Prognostication
11%
Progression Free Survival
32%
Propensity Score Matching
17%
Prostate Cancer
40%
Prostate Specific Antigen
23%
Prostatectomy
21%
Radiation Therapy
14%
Recurrence Free Survival
20%
Recurrent Disease
53%
Retrospective Study
46%
Survival Rate
19%
Transitional Cell Carcinoma
68%
Transurethral Resection
24%
Urinary Tract Cancer
20%
Urologic Oncology
15%
Keyphrases
Adverse Events
17%
Antimicrobial
22%
Bacillus
20%
Bacillus Calmette
76%
Bacillus Calmette-Guérin
15%
Bladder Cancer
39%
Bone Metastasis
23%
Cancer Chemotherapy
14%
Cancer Patients
26%
Cancer-specific Survival
28%
Chemotherapy
22%
Cisplatin
16%
Combination Therapy
16%
Confidence Interval
24%
Hazard Ratio
15%
High Risk
21%
Hokkaido Japan
20%
Immune-oncology
16%
Intravesical
42%
Japan
16%
Japanese Patients
15%
Metastatic Renal Cell Carcinoma (mRCC)
35%
Multi-institutional
20%
Multicenter Retrospective Study
23%
Muscle-invasive Bladder Cancer
29%
Neoadjuvant
15%
Neoadjuvant Chemotherapy
26%
Nephroureterectomy
23%
Nivolumab
24%
Non-muscle Invasive Bladder Cancer (NMIBC)
99%
Oncological Outcomes
23%
Overall Survival
37%
Pembrolizumab
27%
Poor Prognosis
18%
Progression-free Survival
31%
Propensity Score Matching
20%
Prostate Cancer
25%
Radical Cystectomy
67%
Radical Prostatectomy
17%
Radiotherapy
15%
Recurrence-free Survival
23%
Renal Cell Carcinoma
25%
Sexually Transmitted Infections
20%
Surgical Site Infection
21%
Transurethral Resection of Bladder Tumor (TURBT)
15%
Tyrosine Kinase Inhibitor
15%
Upper Tract Urothelial Carcinoma
21%
Urologic Oncology
15%
Urological Cancer
20%
Urothelial Carcinoma
47%
Pharmacology, Toxicology and Pharmaceutical Science
Abiraterone Acetate
10%
Adverse Event
9%
Androgen
11%
Avelumab
6%
Axitinib
13%
Bladder Cancer
36%
Bladder Tumor
7%
Bloodstream Infection
10%
Bone Metastasis
12%
C Reactive Protein
7%
Cabozantinib
5%
Cancer Specific Survival
27%
Carcinoma in Situ
6%
Castration Resistant Prostate Cancer
26%
Chemotherapy
33%
Cisplatin
16%
Cohort Study
5%
Combination Therapy
16%
Disease
20%
Disease Exacerbation
5%
Diseases
8%
Docetaxel
11%
Epididymitis
10%
Gemcitabine
11%
Ipilimumab
19%
Kidney Metastasis
40%
Malignant Neoplasm
11%
Muscle Invasive Bladder Cancer
10%
Mycobacterium Bovis BCG
15%
Neoplasm
22%
Nivolumab
44%
Non Muscle Invasive Bladder Cancer
79%
Overall Survival
46%
Pembrolizumab
11%
Prednisolone
12%
Prednisone
9%
Progression Free Survival
44%
Prostate Cancer
25%
Prostate Specific Antigen
18%
Protein Tyrosine Kinase Inhibitor
16%
Radium Chloride Ra 223
10%
Recurrence Free Survival
21%
Recurrent Disease
37%
Renal Cell Carcinoma
32%
Retrospective Study
51%
Scleroderma
10%
Sunitinib
11%
Surgical Infection
10%
Survival Rate
27%
Transitional Cell Carcinoma
44%
